Comparison of the Efficacy and Safety of Ivermectin to Permethrin

This study has been completed.
Information provided by:
University Ghent Identifier:
First received: December 4, 2005
Last updated: December 19, 2007
Last verified: December 2007
Comparison of the efficacy and safety of a single administration of ivermectin to a single administration of permethrin for the treatment of scabies

Condition Intervention Phase
Drug: Administration of ivermectin or permethrin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Double Dummy Study to Compare the Efficacy and Safety of a Single Administration of Ivermectin to a Single Administration of Permethrin for the Treatment of Scabies

Resource links provided by NLM:

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • Clinical healing of the skin injuries [ Time Frame: on day28 ]

Secondary Outcome Measures:
  • Decrease of itching [ Time Frame: on day28 ]
  • Amelioration of the life quality [ Time Frame: on day28 ]
  • Number and gravity of adverse events

Enrollment: 160
Study Start Date: July 2004
Study Completion Date: May 2005
Detailed Description:
Administration of ivermectin or permethrin on day0 Clinical examination and pictures on day0, day14 and day28 Blood sample on day0 VAS for pruritus, DLQI and SF-36 on day0, day14 and day28

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

At least one of the following inclusion criteria:

  • Scabies tunnels
  • Positive microscopic examination (acarids, faeces or ova)

At least two of the three following inclusion criteria:

  • Non-specific injuries with a typical distribution pattern
  • Serious itching which increases during the night
  • Family or contacts with similar complaints

Exclusion Criteria:

  • Treatment for scabies < 4 weeks ago
  • Treatment with corticoids < 1 week ago
  • Pregnancy
  • Breast-feeding
  • HIV
  • Serious immunodepressive patients
  • Sensitivity or allergy to one of the components of the study medication
  • Damage of the central nerve system
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262418

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Ghent
Principal Investigator: Jean-Marie Naeyaert, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
No publications provided Identifier: NCT00262418     History of Changes
Other Study ID Numbers: 2004/212
Study First Received: December 4, 2005
Last Updated: December 19, 2007
Health Authority: Belgium: Institutional Review Board

Additional relevant MeSH terms:
Ectoparasitic Infestations
Mite Infestations
Parasitic Diseases
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Anti-Infective Agents
Antiparasitic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 25, 2015